Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Esperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 34 cents. The mean expectation of seven analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -21 cents to -9 cents per share.

• Revenue fell 52.8% to $65.00 million from a year ago; analysts expected $54.34 million.

• Esperion Therapeutics Inc's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of $40.46 million.

• Esperion Therapeutics Inc shares had fallen by 27.1% this quarter and lost 52.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.00

This summary was machine generated from LSEG data May 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)